Table 4.
Comparison of Echocardiographic Parameters Before and After Osimertinib Administration
| NSCLC (N = 36) |
Non-CTRCD (n = 32) |
CTRCD (n = 4) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Before | After | p Value∗ | Before | After | p Value† | Before | After | p Value‡ | |
| LVEF, % | 69.4 ± 4.2 | 63.4 ± 10.5 | <0.001 | 69.8 ± 4.0 | 67.9 ± 5.5 | 0.004 | 66.3 ± 5.1 | 40.3 ± 9.1 | <0.001 |
| LVIDd, mm | 42.6 ± 4.5 | 44.5 ± 5.2 | 0.005 | 42.4 ± 4.4 | 43.9 ± 4.8 | 0.003 | 44.0 ± 4.9 | 48.8 ± 7.2 | 0.344 |
| LVIDs, mm | 26.3 ± 3.3 | 29.1 ± 5.6 | <0.001 | 26.0 ± 3.1 | 27.8 ± 3.9 | <0.001 | 28.2 ± 4.3 | 39.3 ± 7.5 | 0.001 |
| E peak, cm/s | 66.7 ± 18.0 | 73.4 ± 19.2 | 0.017 | 67.3 ± 18.2 | 73.1 ± 17.9 | 0.035 | 62.4 ± 18.1 | 75.7 ± 31.4 | 0.858 |
| Dct, ms | 222.6 ± 54.0 | 217.9 ± 39.2 | 0.625 | 225.2 ± 55.9 | 216.6 ± 31.3 | 0.333 | 201.5 ± 32.4 | 228.5 ± 87.3 | 0.817 |
| E/A ratio | 0.90 ± 0.26 | 1.04 ± 0.36 | 0.013 | 0.90 ± 0.28 | 1.04 ± 0.38 | 0.047 | 0.70 ± 0.14 | 0.98 ± 0.26 | 0.870 |
| HR, beats/min | 74.2 ± 10.8 | 75.1 ± 14.6 | 0.600 | 74.3 ± 11.3 | 74.3 ± 14.5 | 0.875 | 73.5 ± 7.0 | 81.6 ± 16.5 | 0.442 |
Values are mean ± SD.
CTRCD = cancer therapeutics-related cardiac dysfunction; Dct = deceleration time; E peak = peak velocity of early transmitral flow; E/A ratio = peak velocities of early-to-late ratio of transmitral flow; HR = heart rate; LVEF = left ventricular ejection fraction; LVIDd = left ventricular end-diastolic dimension; LVIDs = left ventricular end-systolic dimension.
∗
p value comparing echocardiographic parameters before and after osimertinib in 36 NSCLC patients with serial monitoring.
†
p value comparing parameters before and after in 32 patients without CTRCD.
‡
p value comparing parameters between after in 32 non-CTRCD and after in 4 with CTRCD.